ReviewAdvanced healthcare materials2025
Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.
Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting NETosis in the Lung: Respiratory Delivery of Neutrophil-Specific NEBP-Liposomes for Enhanced Therapy of Acute Lung Injury.Molecular pharmaceutics · 2026Article
- Cell-Specific Extracellular Vesicles Targeting Strategies for Immune Modulation in Inflammatory Diseases.Pharmaceutics · 2026Review
- Oxidative stress-driven epigenetic reprogramming of immune cells in COPD: from epitranscriptomic and metabolic crosstalk to treatable traits.Frontiers in immunology · 2026Review
- Smart nanovehicles crossing the barricade: precision targeting of neuroinflammation for ischemic stroke diagnostics and therapeutics.Journal of nanobiotechnology · 2025Review
- Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.Advanced healthcare materials · 2025Review
- From "immune silence" to "immune dialogue": modification strategies for bone substitutes based on bone immunomodulatory characteristics.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neutrophils, the most abundant leukocytes in human blood, play a critical role in the initial response to acute infection and injury. Activated neutrophils exert three primary effector functions: phagocytosis, degranulation of proteolytic enzymes into pericellular spaces, and generation of neutrophil extracellular traps (NETs). However, dysregulated neutrophil function can lead to tissue damage and inflammation, resulting in organ dysfunction that ultimately contributes to the progression of various diseases. Given the implication of neutrophils in the pathogenesis of diseases arising from chronic inflammation, exploring emerging therapies targeting these cells is critical for developing more effective treatment options. This review highlights nanotechnology-based therapeutic strategies aimed at modulating neutrophil activity and NET formation, with a focus on nanoparticles (NPs) and hydrogels. NPs-based delivery systems can regulate excessive neutrophil activity through targeted delivery of anti-inflammatory drugs, alteration of gene expression, induction of cell death, or inhibition of neutrophil recruitment. Additionally, various nanotechnology-based therapeutics can inhibit NET formation or degrade NETs following neutrophil activation. NPs can also be internalized by neutrophils and utilized as carriers, facilitating localized therapeutic delivery as neutrophils are recruited to inflammatory sites. The importance of targeting or harnessing neutrophils are explained and we discuss therapeutic strategies to control their activity, which may aid in designing future treatments for neutrophil-mediated inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.